Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease

Summary

Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) has been widely used as an anti-platelet agent for the treatment of PAD. SID142 is a new controlled-release product improved patient's convenience and disadvantage of dosage regimen of previous drug. The aim of this study was to compare the efficacy and safety of SID142 and Rinexin® Tab in patients with PAD

Timeline

Start

2017-02-20

Primary completion

2018-10-15

Completion

2018-10-15

Outcome

Met primary endpoint

paper Analysis of the change in lower extremity pain at 12 weeks compared with baseline revealed that SID142 was not inferior to Renexin PMID 35410753 ↗

Publications

• Kook H, Yu CW, Choi D, Ahn TH, Chang K, Cho JM, Kim SJ, Park CG, Cho DK, Kim SH, Lee HC, Jin HY, Chae IH, Kwon K, Ahn SG, Kim JH, Lee SR, Kim JS, Kim SY, Lim SW. Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial. Clin Ther. 2022 Apr;44(4):508-528. doi: 10.1016/j.clinthera.2022.01.016. Epub 2022 Apr 9.

Drugs

Indications